newsfilter
← Latest News
Business Wire·

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

– Acquisition Builds on Gilead's Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful